Non-steroidal mineralocorticoid receptor antagonists

Expert Opinion on Therapeutic Patents

Volumn 17, Issue 1, 2007, Pages 17-23

  Meyers, Marvin J ^a   Hu, Xiao ^a  

^a PFIZER INC   (United States)

Author keywords

Aldosterone; Eplerenone; Heart failure; Hypertension; Mineralocorticoid; Mineralocorticoid receptor antagonist; Spironolactone

Indexed keywords

3 BENZYL INDOLE DERIVATIVE; 3,3 BISARYL OXINDOLE DERIVATIVE; 4 ARYL 1,4 DIHYDROPYRIDINE DERIVATIVE; ALDOSTERONE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENZOXAZINE DERIVATIVE; BENZOXAZINETHIONE DERIVATIVE; BENZOXAZINONE DERIVATIVE; DIBENZOSUBERANE DERIVATIVE; DIHYDROPYRIDINE DERIVATIVE; DIHYDROQUINOLINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; LOSARTAN; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; NEW DRUG; OXEPINE DERIVATIVE; OXINDOLE; PLACEBO; PYRROLE DERIVATIVE; SODIUM CHLORIDE; SPIRONOLACTONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WATER;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG CLASSIFICATION; DRUG DESIGN; DRUG IDENTIFICATION; DRUG INFORMATION; DRUG MARKETING; DRUG POTENTIATION; DRUG RESEARCH; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; FLUID BALANCE; HEART FAILURE; HUMAN; HYPERTENSION; MONOTHERAPY; NONHUMAN; PATENT; PHYSICAL CHEMISTRY; REVIEW; SCIENTIFIC LITERATURE; SODIUM BALANCE; UNSPECIFIED SIDE EFFECT;

EID: 33846180691     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.17.1.17     Document Type: Review

References (28)

1. BRILLA CG, PICK R, TAN LB, JANICKI JS, WEBER KT: Remodeling of the rat right and left ventricles in experimental hypertension. Circ. Res. (1990) 67(6):1355-1364.
2. ROCHA R, RUDOLPH AE, FRIERDICH GE et al.: Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am. J. Physiol. Heart Circ. Physiol. (2002) 283(5):H1802-H1810.
3. NISHIZAKA MK, ZAMAN MA, GREEN SA, RENFROE KY, CALHOUN DA. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation (2004) 109(23):2857-2861.
4. HU X, LI S, MCMAHON EG, LALA DS, RUDOLPH AE: Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone. Mini Rev. Med. Chem. (2005) 5(8):709-718.
5. WEINBERGER MH, RONIKER B, KRAUSE SL, WEISS RJ: Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am. J. Hypertens. (2002) 15(8):709-716.
6. WHITE WB, CARR AA, KRAUSE S et al: Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am. J. Cardiol. (2003) 92(1):38-42.
7. WHITE WB, DUPREZ D, ST HILLAIRE R et al.: Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension (2003) 41(5):1021-1026.
8. PITT B, REICHEK N, WILLENBROCK R et al.: Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy. the 4E-left ventricular hypertrophy study. Circulation (2003) 108(15):1831-1838.
9. WILLIAMS GH, BURGESS E, KOLLOCH RE et al.: Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am. J. Cardiol. (2004) 93(8):990-996.
10. FLACK JM, OPARIL S, PRATT JH et al: Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J. Am. Coll. Cardiol, (2003) 41(7):1148-1155.
11. WEINBERGER MH, WHITE WB, RUILOPE LM et al.: Effects of eplerenone versus losartan in patients with low-renin hypertension. Am. Heart J. (2005) 150(3):426-433.
12. KRUM H, NOLLY H, WORKMAN D et al: Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension (2002) 40(2):117-123.
13. BURGESS ED, LACOURCIERE Y, RUILOPE-URIOSTE LM et al: Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension. Clin. Ther. (2003) 25(9):2388-2404.
14. CHOBANIAN AV, BAKRIS GL, BLACK HR et al: The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report. Jama (2003) 289(19):2560-2572.
15. OUZAN J, PERAULT C, LINCOFF AM, CARRE E, MERTES M: The role of spironolactone in the treatment of patients with refractory hypertension. Am. J. Hypertens. (2002) 15(4 Pt 1):333-339.
16. NISHIZAKA MK, ZAMAN MA, CALHOUN DA: Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am. J. Hypertens. (2003) 16(11 Pt 1):925-930.
17. PITT B, ZANNAD F, REMME WJ et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. (1999) 341(10):709-717.
18. PITT B, REMME W, ZANNAD F et al: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. (2003) 348(14):1309-1321.
19. EPSTEIN M, BUCKALEW JV, MARTINEZ F et al: Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria. Am. J. Hypertens. (2002) 15(1):A24.
20. KEIDAR S, KAPLAN M, PAVLOTZKY E et al: Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation (2004) 109(18):2213-2220.
21. RAJAGOPALAN S, DUQUAINE D, KING S, PITT B, PATEL P: Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation (2002) 105(18):2212-2216.
22. KEIDAR S, HAYEK T, KAPLAN M et al.: Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc. Pharmacol. (2003) 41(6):955-963.
23. TAKAI S, JIN D, MURAMATSU M et al.: Eplerenone inhibits atherosclerosis in nonhuman primates. Hypertension (2005) 46(5):1135-1139.
24. SUZUKI J, IWAI M, MOGI M et al: Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler. Thromb. Vasc. Biol. (2006) 26(4):917-921.
25. YOUNG WF Jr: Primary aldosteronism treatment options. Growth Horm. IGF Res. (2003) 13 (Suppl. A):S102-S108.
26. PALMER BF: Pathogenesis of ascites and renal salt retention in cirrhosis. J. Investig. Med. (1999) 47(5):183-202.
27. JADHAV PK, MATTHEWS DP, GREEN J et al: Discovery of orally bioavailable, non-steroidal mineralo-corticoid receptor antagonist: a tale of three platforms. 231st American Chemical Society National Meeting. Altanta (2006) MEDI 179.
28. NEEL DA, BROWN ML, LANDER PA et al: 3,3-Bisaryloxindoles as mineralocorticoid receptor antagonists. Bioorg. Med. Chem. Lett. (2005) 15(10):2553-2557.